Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
<< Back to Results
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective than gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating pancreatic cancer.
https://www.clinicaltrials.gov/ct2/show/NCT02562716
Contact Phone: 218-786-3308 | 1-844-681-7944
Email: cancertrials@essentiahealth.org
Locations: Essentia Health Cancer Centers
Disclosures:
None
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.
